Cytochrome P450 enzymes (P450s) are metabolic enzymes that process the majority of FDA-approved, small-molecule drugs (Nebert and Russell, 2002). Understanding how these enzymes modify molecule structure is key to the development of safe, effective

Understanding the metabolism of small molecules is of paramount importance to the drug discovery industry and mitigates the risk of costly late failure in drug development projects due to adverse ADMET properties. Modern experimental approaches enable

Abemaciclib was approved by the US Food and Drug Administration in 2015 as an advanced treatment for metastatic breast cancer. Identification and characterization of limited numbers of abemaciclib metabolites have been reported in the literature. Therefore,